Pancreatic Cancer Research

ResearcherUniversity of MichiganActive in the last 2 years

Haoqiang Ying

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-0616-2310; OpenAlex author ID A5078004886; NIH RePORTER profile ID 10311153. Sources: OpenAlex.

Their work

Papers
46 (first author 2, last author 5)
Trials
0
Grants
2
Labs led
1
Collaborators
191
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: 3 papers · 2015: 1 paper · 2016: 2 papers · 2017: 4 papers, 1 grant · 2018: 2 papers · 2019: 5 papers · 2020: 3 papers · 2021: 5 papers · 2022: 1 paper · 2023: 4 papers, 1 grant · 2024: 3 papers · 2025: 3 papers · 2026: 8 papers

Papers 46

  1. Syndecan-1-targeted therapeutic antibody impairs macropinocytosis and elicits antitumor immunity in pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2026.102613↗
  2. All-trans retinoic acid destabilizes ADAR1 protein through retinoylation-mediated USP7 dissociation and improves immunotherapy in pancreatic cancer. Co-author DOI 10.1038/s41467-026-72271-5↗
  3. Author Correction: Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Co-author DOI 10.1038/s41586-026-10488-6↗
  4. Author Correction: Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Co-author DOI 10.1038/s41586-026-10995-6↗
  5. Author Correction: Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. Co-author DOI 10.1038/s41586-026-11134-x↗
  6. Site-Specific Outcomes and Genomics in Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1093/oncolo/oyag423↗
  7. GFER Represents a Target for Dual Disruption of Redox Homeostasis and Reactivation of the Immune Response in Pancreatic Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-24-4211↗
  8. The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/2767-9764.crc-25-0278↗
  9. Genetics and biology of pancreatic ductal adenocarcinoma. Co-author DOI 10.1101/gad.351863.124↗
  10. KRAS Inhibition Activates an Actionable CD24 "Do Not Eat Me" Signal in Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-25-2024↗
  11. KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13045-025-01696-0↗
  12. Targeting a chemo-induced adaptive signaling circuit confers therapeutic vulnerabilities in pancreatic cancer. Co-author DOI 10.1038/s41421-024-00720-w↗
  13. All-trans retinoic acid-mediated ADAR1 degradation synergizes with PD-1 blockade to suppress pancreatic cancer Co-author DOI 10.1101/2024.10.20.619300↗
  14. Clonal dominance defines metastatic dissemination in pancreatic cancer. Co-author DOI 10.1126/sciadv.add9342↗
  15. KRAS G12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells. Co-author DOI 10.1016/j.ccell.2023.07.002↗
  16. Elimination of oncogenic KRAS in genetic mouse models eradicates pancreatic cancer by inducing FAS-dependent apoptosis by CD8+ T cells. Co-author DOI 10.1016/j.devcel.2023.07.025↗
  17. Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer. Co-author DOI 10.1038/s43018-022-00500-z↗
  18. Tumor-associated nonmyelinating Schwann cell-expressed PVT1 promotes pancreatic cancer kynurenine pathway and tumor immune exclusion. Co-author DOI 10.1126/sciadv.add6995↗
  19. Metabolic requirement for GOT2 in pancreatic cancer depends on environmental context. Co-author DOI 10.7554/elife.73245↗
  20. Loss of the wild-type KRAS allele promotes pancreatic cancer progression through functional activation of YAP1. Co-author DOI 10.1038/s41388-021-02040-9↗
  21. PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41467-021-24798-y↗
  22. Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance. Co-author DOI 10.1038/s41467-021-27349-7↗
  23. Targeting Glucose Metabolism Sensitizes Pancreatic Cancer to MEK Inhibition. Last author DOI 10.1158/0008-5472.can-20-3792↗
  24. Hyaluronic acid fuels pancreatic cancer cell growth. Co-author DOI 10.7554/elife.62645↗
  25. Recent insights into the biology of pancreatic cancer. Last author DOI 10.1016/j.ebiom.2020.102655↗
  26. Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Co-author DOI 10.1038/s41591-020-0947-8↗
  27. Oncogenic KRAS-Driven Metabolic Reprogramming in Pancreatic Cancer Cells Utilizes Cytokines from the Tumor Microenvironment. Co-author DOI 10.1158/2159-8290.cd-19-0297↗
  28. Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. Co-author DOI 10.1038/s41586-019-1062-1↗
  29. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Co-author DOI 10.1038/s41591-019-0368-8↗
  30. Mitochondrial fusion exploits a therapeutic vulnerability of pancreatic cancer. Co-author DOI 10.1172/jci.insight.126915↗
  31. YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma. Last author DOI 10.1172/jci.insight.130811↗
  32. Glucose Metabolism in Pancreatic Cancer. Last author DOI 10.3390/cancers11101460↗
  33. Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2018.02.012↗
  34. Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis. Co-author DOI 10.1038/s41467-018-07472-8↗
  35. Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. Co-author DOI 10.1038/nature21052↗
  36. Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Co-author DOI 10.1038/nature21064↗
  37. Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma. First author DOI 10.1038/ncomms14437↗
  38. A tumor vessel-targeting fusion protein elicits a chemotherapeutic bystander effect in pancreatic ductal adenocarcinoma. Co-author PMID 28401019↗
  39. KRAS-related proteins in pancreatic cancer. First author DOI 10.1016/j.pharmthera.2016.09.003↗
  40. Functional annotation of rare gene aberration drivers of pancreatic cancer. Co-author DOI 10.1038/ncomms10500↗
  41. Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer. Co-author DOI 10.1158/0008-5472.can-14-1854↗
  42. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Co-author DOI 10.1016/j.cell.2014.06.003↗
  43. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Co-author DOI 10.1038/nature13611↗
  44. Neuroplastic changes occur early in the development of pancreatic ductal adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-13-2050↗
  45. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Co-author DOI 10.1038/nature12040↗
  46. PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network. Co-author DOI 10.1158/2159-8290.cd-11-0031↗

Grants 2

  1. Elucidating and targeting subtype-specific driver in pancreatic cancer R01CA214793↗
  2. The Regulation of Oncogene Addiction by YAP Pathway in Pancreatic Cancer AWARD pancan:2017-haoqiang-ying-md-phd-the-regulation-of-oncogene-addiction-by-

Closest collaborators

The 25 strongest of 191 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Anirban Maitra · 22 shared papers, 2017–2026 · strength 3.09
  2. Huamin Wang · 19 shared papers, 2014–2026 · strength 2.23
  3. Ronald Anthony Depinho · 20 shared papers, 2011–2026 · strength 2.01
  4. Wantong Yao · 13 shared papers, 2014–2026 · strength 1.66
  5. Giulio Francesco Draetta · 14 shared papers, 2014–2026 · strength 1.56
  6. Timothy Paul Heffernan · 14 shared papers, 2014–2026 · strength 1.49
  7. Andrea Viale · 13 shared papers, 2014–2026 · strength 1.44
  8. Giannicola Genovese · 11 shared papers, 2014–2026 · strength 1.26
  9. Jason B. Fleming · 14 shared papers, 2013–2026 · strength 1.23
  10. Yongkun Wei · 6 shared papers, 2018–2026 · strength 0.96
  11. Mien‐Chie Hung · 8 shared papers, 2017–2026 · strength 0.90
  12. Jun Yao · 9 shared papers, 2017–2025 · strength 0.89
  13. Alessandro Carugo · 9 shared papers, 2014–2026 · strength 0.88
  14. Ya’an Kang · 9 shared papers, 2013–2026 · strength 0.83
  15. Ching-Fei Li · 4 shared papers, 2024–2026 · strength 0.81
  16. Alec C. Kimmelman · 8 shared papers, 2011–2026 · strength 0.80
  17. Michael P. Kim · 7 shared papers, 2018–2025 · strength 0.77
  18. Prasenjit Dey · 6 shared papers, 2017–2026 · strength 0.70
  19. Paul J. Chiao · 5 shared papers, 2017–2026 · strength 0.69
  20. Costas Andreas Lyssiotis · 8 shared papers, 2013–2026 · strength 0.68
  21. Virginia Giuliani · 6 shared papers, 2014–2026 · strength 0.67
  22. Dihua Yu · 4 shared papers, 2023–2026 · strength 0.63
  23. Raghu Kalluri · 3 shared papers, 2023–2025 · strength 0.58
  24. Abdelrahman M.G. Yousef · 3 shared papers, 2025–2026 · strength 0.53
  25. Yan Liang · 6 shared papers, 2019–2021 · strength 0.51

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.